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Abstract
Background: Increased fertility rates in HIV-infected women receiving antiretroviral therapy (ART) have been attributed to
improved immunological function; it is unknown to what extent the rise in pregnancy rates is due to unintended
pregnancies.
Methods: Non-pregnant women ages 18–35 from four public-sector ART clinics in Johannesburg, South Africa, were
enrolled into a prospective cohort and followed from August 2009–March 2011. Fertility intentions, contraception and
pregnancy status were measured longitudinally at participants’ routine ART clinic visits.
Findings: Of the 850 women enrolled, 822 (97%) had at least one follow-up visit and contributed 745.2 person-years (PY) at-
risk for incident pregnancy. Overall, 170 pregnancies were detected in 161 women (incidence rate [IR]: 21.6/100 PY [95%
confidence interval (CI): 18.5–25.2]). Of the 170 pregnancies, 105 (62%) were unplanned. Unmet need for contraception was
50% higher in women initiating ART in the past year as compared to women on ART.1 year (prevalence ratio 1.5 [95% CI:
1.1–2.0]); by two years post-ART initiation, nearly one quarter of women had at least one unplanned pregnancy. Cumulative
incidence of pregnancy was equally high among recent ART initiators and ART experienced participants: 23.9% [95% CI:
16.4–34.1], 15.9% [12.0–20.8], and 21.0% [16.8–26.1] for women on ART 0–1 yr, .1 yr–2 yrs, and .2 yrs respectively (log-
rank, p=0.54). Eight hormonal contraceptive failures were detected [IR: 4.4 [95% CI: 2.2–8.9], 7/8 among women using
injectable methods. Overall 47% (80/170) of pregnancies were not carried to term.
Conclusions: Rates of unintended pregnancies among women on ART are high, including women recently initiating ART
with lower CD4 counts and higher viral loads. A substantial burden of pregnancy loss was observed. Integration of
contraceptive services and counselling into ART care is necessary to reduce maternal and child health risks related to
mistimed and unwanted pregnancies. Further research into injectable contraceptive failures on ART is warranted.
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Introduction
Women account for 60% of HIV-infections in Sub-Saharan
Africa [1]. Contraception is critical to the health and empower-
ment of all women, particularly women infected with HIV.
Preventing unintended pregnancies amongst women living with
HIV is one of four components of the World Health Organiza-
tion’s (WHO) prevention of mother-to-child transmission
(PMTCT) strategy and has been shown to be a cost-effective
approach to HIV prevention [2–4]. Integration of HIV and
reproductive health services can increase contraceptive uptake, but
standard practice in most health systems is to provide separate
services for HIV treatment and contraception [5,6].
Individuals living with HIV vary in their desire for more
children [7–9]. Lower fertility rates have been reported in HIV-
positive women, however evidence suggests that pregnancy
incidence increases after ART initiation [10–12]. For HIV
infected women choosing to become pregnant, planning a
conception at a time when her CD4 count is high and viral load
low contributes to maternal wellbeing and to the prevention of
HIV transmission to the unborn child [13,14]. For these reasons
there has been increasing recognition of the importance of
appropriately-timed pregnancies.
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e36039While pregnancy rates are increasing among women on ART, it
remains unclear to what extent this phenomenon is due to choice
or due to an increase in unplanned pregnancies. Women may have
experienced HIV-related sub-fertility in the past and may not
anticipate an increased pregnancy risk upon ART initiation.
Although women on ART are already linked into the health care
system and therefore should have contraceptive access, limited
integration of services and a focus on condoms alone as a method
to prevent HIV transmission may result in inadequate contracep-
tive provision in this population and an increased risk for
unintended pregnancies.
The objectives of this study are to determine the incidence of
unplanned pregnancies in HIV-positive women on ART in South
Africa, and to assess contraceptive use and associations with
unplanned pregnancy in this population.
Methods
Ethics Statement
The study protocol was approved by the University of the
Witwatersrand Human Research Ethics Committee, Johannes-
burg, South Africa. Written informed consent was obtained from
all participants.
Study design and recruitment
Data presented are from a prospective cohort study conducted
in four government-run ART clinics in Johannesburg, South
Africa. ART is provided free of charge by the government in
South Africa based on immunological or clinical status. At the
time of study enrolment, non-pregnant women were eligible for
lifelong ART initiation with a CD4 count #200 cells/ml or WHO
clinical stage 4 diagnosis [15].
Enrolment took place from August 2009 to January 2010 at two
ART initiation sites and two ART down-referral sites where
patients continue treatment once they are clinically stable. The
down-referral sites are near to the study initiation sites and are
comprised of demographically similar populations. All women of
child-bearing age in clinic waiting rooms were informed by
research assistants of the opportunity to participate in a study
related to women’s health and ART experience. Further screening
and informed consent of interested individuals occurred in private
rooms.
Our sample size was determined to compare pregnancy
incidence rates across ART regimens. The study targeted 850
participants for enrolment. For the present analysis, based on a
priori expected cumulative pregnancy incidence of 15%, and an
anticipated loss-to-follow-up of 15%, we would have .80% power
to detect a 10% difference in pregnancy survival curves between
women not trying to conceive with met and unmet contraceptive
need. Women were eligible for participation if at enrolment they
were: between 18–35 years, not pregnant, had not delivered within
the three months prior, not breast-feeding, on ART or being
initiated onto ART, sexually active in the past twelve months, and
had not undergone prior tubal ligation, hysterectomy, bi-lateral
oophorectomy, or otherwise been diagnosed permanently infertile.
Those with a positive pregnancy test at time of recruitment were
not eligible for study enrolment and were referred to antenatal
care or other appropriate services. Non-pregnant women
completed a baseline interview and were enrolled for study
follow-up. Approximately 9,000 persons were receiving care at
study sites, of which around 3,000 were women between the ages
18–35 years. Overall 907 women were consented to participate in
the study. Of these women, 57 (6%) were excluded as they were
determined to be ineligible and 850 women were enrolled
(Figure 1).
Data Collection and Follow-up
Baseline interviews were conducted in English, Zulu or Sotho
by trained study staff in private clinic rooms. Interviews covered
demographics, ART experience, obstetrics history, contraceptive
use, fertility intentions, communication with providers and
questions about partnership dynamics.
Women were seen by study staff during routine clinic visits over
one-year of follow-up. The median time between visits was 1.8
months [interquartile range (IQR) 0.9–2.1]. Contraceptive use,
current fertility intentions and pregnancy testing were assessed at
each study visit. Participants were referred for antenatal care or
other support services as indicated. Study follow-up for non-
pregnant women was concluded at the first clinic visit after
completing one year of follow-up. Pregnant women were followed
through the duration of pregnancy to assess reproductive
outcomes. Overall, 91% of women contributed two or more
follow-up visits after their baseline visit.
Date of ART initiation was confirmed through clinical and
pharmacy records. ART regimen information, CD4 cell count and
viral load were collected longitudinally and confirmed through
pharmacy and laboratory records. Patient files were reviewed to
collect additional clinical and treatment history and to abstract any
pregnancies or reproductive health outcomes during study follow-
up that may have been missed.
Variable Measures
Pregnancy was determined using urine-based tests administered
by study staff (One Step hCG Urine Pregnancy Test, Atlas Link Technology,
Beijing). Positive pregnancy tests were confirmed through repeat
testing. Conception dates were assigned to two weeks following the
last menstrual period (LMP) or if unknown, to 266 days before the
due date determined by ultrasound and recorded in antenatal
records.
Contraceptive use was self-reported. Women were considered to
be using a reliable method of contraception at baseline if they
reported using hormonal contraception (HC), consistent condom
use, or both. Hormonal method use included depot-medroxypro-
gesterone (DMPA) and norethisterone enantate (NET-EN)
injectable methods, combined oral contraceptives (COCs), and
hormonal implants. There was only one participant using the
intrauterine device (IUD) who for the purposes of this analysis has
been grouped with HC users. Consistent condom use at baseline
was defined as using a condom during the last sexual act and
reporting condom use every time over the past twelve months.
This study considered unmet need for contraception to include
all women in situations of risk for an unplanned pregnancy.
Specifically, baseline unmet need for contraception included
women at enrollment who were: (i) married or living with a
partner, or had sexual intercourse in the past three months, and (ii)
reported that they were not trying to conceive, and (iii) were not
using a reliable form of contraception as defined above.
Statistical analysis
Comparisons of medians and categorical variables were
calculated using non-parametric k-sample tests of equality of
medians and chi-squared tests respectively. Any comparisons
between groups presented in the text use chi-squared tests unless
otherwise noted.
Incidence rates were calculated for the first incident pregnancy
per 100 person-years (PYs). Rates for planned and unplanned
pregnancies included only time in the denominator during which
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pregnancies respectively.
Survival analysis was used to assess time-to-pregnancy and time-
to-unplanned pregnancy by ART duration and contraceptive use.
The origin for the survival analyses was time of study enrolment.
Events were defined as the date of pregnancy. Persons were
censored from the analysis if they were lost to follow-up, withdrew
from the study, died or upon study completion. Kaplan-Meier
(KM) curves were used to plot failure curves. Risk sets for the KM
curves plotting the incidence of unplanned pregnancy include only
periods of person-time contributed when women were not trying
to conceive and were thus at risk for an unplanned pregnancy.
Log-rank tests were used in the KM analyses to assess the equality
of failure functions across groups. Exposures for fertility intentions,
contraceptive use and time-on-ART are time-varying in the KM
analyses.
Univariate and multivariate analyses to assess predictors of
baseline unmet contraceptive need were calculated using robust
poisson regression models to estimate prevalence ratios (PRs) and
adjusted prevalence ratios (aPRs). Poisson regression was the
Table 1. Description of baseline cohort characteristics by months-on-antiretroviral therapy (ART), South Africa.
Characteristics at time
of study enrollment All participants (n=850) Recent ART Initiators ART Experienced p-value
(0–12 mo) (.12 mo–24 mo) (.24 mo)
n=399 n=240 n=211
Median (IQR)
a
Age, yrs 30 (27–33) 30 (27–32) 30 (27–33) 32 (28–34) 0.008
Monthly income, USD 270 (149–473) 270 (135–405) 270 (162–473) 323 (189–541) 0.012
Time on ART, months 13 (5–24) 5 (2–8) 17 (14–20) 37 (30–48) ,0.001
CD4 count at enrollment, cells/ml 320 (178–469) 183 (124–301) 381 (284–515) 503 (366–650) ,0.001
Most recent HIV-1 Viral load,
log10 (copies/ml)
b
1.7 (1.7–1.8) 1.7 (1.7–2.8) 1.7 (1.7–1.7) 1.7 (1.7–1.7) ,0.001
Number of living children 1 (1–2) 1 (0–2) 1 (1–2) 1 (1–2) 0.013
Relationship duration, yrs
c 4 (2–7) 3 (1–6) 5 (2–7) 4 (2–8) 0.065
Time since last pregnancy, yrs
d 4 (2–8) 5 (2–8) 3 (1–7) 3 (2–7) ,0.002
n( % )
Employed 510 (60) 222 (56) 145 (60) 143 (68) 0.014
Education completed
None – grade 10 218 (26) 121 (30) 55 (23) 42 (20) 0.020
Grade 11–12 528 (62) 232 (58) 160 (67) 136 (64)
Post-grad degree or certificate 104 (12) 46 (12) 136 (10) 33 (16)
In a relationship 790 (93) 365 (91) 227 (95) 198 (94) 0.280
Multiple current partners 100 (12) 48 (12) 18 (8) 34 (16) 0.018
Sexually active past 3 mos. 758 (89) 345 (86) 221 (92) 192 (91) 0.053
Married/Cohabitating 378 (44) 185 (46) 102 (43) 91 (43) 0.574
Disclosure to main partner
c 640 (81) 294 (81) 189 (83) 157 (79) 0.555
Partner HIV status
c
HIV-negative 200 (25) 93 (25) 54 (24) 53 (27) 0.881
HIV-positive 312 (40) 141 (39) 90 (39) 81 (41)
Unknown HIV-status 278 (35) 131 (36) 83 (37) 64 (32)
$1 living child with current
partner
c
324 (41) 136 (37) 105 (46) 83 (42) 0.098
Currently trying to conceive 102 (12) 58 (15) 19 (8) 25 (12) 0.044
Using hormonal contraception 243 (29) 91 (23) 82 (34) 70 (33) 0.002
Experienced violence in current
or past relationship
86 (10) 50 (13) 21 (9) 15 (7) 0.076
Pregnant during or since HIV
diagnosis
380 (45) 123 (31) 129 (54) 128 (61) ,0.001
Normal menstrual cycle during
past 3 months
554 (65) 273 (68) 141 (59) 140 (66) 0.042
aIQR=interquartile range;
bn=834;
cRestricted to participants in a current relationship (n=790);
dRestricted to participants with a prior pregnancy (n=760).
doi:10.1371/journal.pone.0036039.t001
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greater than 10% [16]. Variables were included in the multivariate
analysis based on prior hypotheses or demonstrated statistical
significance using a two-sided, a#0.10 threshold in the univariate
analyses. Twenty-three (3%) of participants were missing income
values. As described previously, multiple imputation with Rubin’s
pooling method was used in the regression analyses to restore
missing income values [17,18]. Data were analyzed using Stata
version 11.1 (StataCorp, College Station, Texas, USA).
Results
Study population and follow-up
Of the 850 women enrolled, 822 (97%) had at least one
additional follow-up visit between August 2009 and March 2011.
Participants had a median of six post-enrolment follow-up visits
and contributed a median of 12 months [IQR 9–13] of follow-up
to the cohort.
Table 1 summarizes baseline characteristics of the cohort
overall and by time-on-ART. The average participant was 30
years of age [IQR 27–33] and had one living child [IQR 1–2].
Time-on-ART at baseline in the cohort ranged from 0–7.4 years
(median 1.1 [IQR 0.4–2.0]) and the baseline CD4 cell count
ranged from 3–1451 cells/ml (median 320 [IQR 178–469]).
Women differed substantially at enrolment in their demographic
and clinical characteristics according to time-on-ART. Relation-
ship and marital status, partner HIV-status, disclosure to a
partner, and having a child with a current partner were
characteristics that were comparable across groups (Table 1).
Incidence of pregnancy and time-on-ART
Over the course of follow-up, 170 new pregnancies were
detected in 161 women over 745.2 PY at risk (incidence rate:
21.6/100 PY [95% CI 18.5–25.2]; Figure 1). Of these, 105 (62%)
of the pregnancies were unplanned (incidence rate: 16.1/100 PY
[95% CI 13.2–19.7; Table 2). Amongst all women who conceived,
median-time to first pregnancy was 168 days [IQR 85–260].
Median-time to first unplanned pregnancy was 136 days [IQR 84–
253].
Figure 2 shows the estimated failure functions for time-to-first
pregnancy by covariates of interest. There was no statistically
significant difference in time-to-pregnancy across duration of
ART; cumulative incidence of pregnancy after 12 months of
follow-up for ART 0–1 year, .1 yr–2 years, and .2 years was
23.9% [95% CI 16.4–34.1], 15.9% [95% CI 12.0–20.8], and
21.0% [16.8–26.1] respectively (log rank, p=0.54). Considering
time-on-ART as the time metric rather than study time, by two
years on ART, nearly one quarter of women had at least one
unplanned pregnancy and by three years the number increased to
more than one-third (Figure 2b). To assess the robustness of this
finding, we repeated this analysis excluding those women who had
a prior pregnancy while on ART (n=105) and findings were
similar (results not shown). There were no differences in pregnancy
incidence by time-varying CD4 cell count categories, time-varying
viral load, partners’ baseline HIV-status, nor enrolment site
(results not shown).
Outcomes to-date of the 105 unplanned pregnancies are 38
(36.2%) elective terminations of pregnancy, 19 (18.1%) spontane-
Table 2. Incidence of pregnancy in the cohort of South African women, August 2009–March 2011.
Time-at-risk Events Incidence Rate (per 100 PY)
(Person Years [PY]) [95% Confidence Interval]
Total pregnancies 745.2 161 21.6 [18.5–25.2]
Unplanned pregnancies 602.1 97 16.1 [13.2–19.7]
Planned pregnancies 143.2 64 44.7 [35.0–57.1]
doi:10.1371/journal.pone.0036039.t002
Figure 1. Study flow diagram of enrollment and follow-up.
doi:10.1371/journal.pone.0036039.g001
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(40.0%) live births, and 4 (3.8%) on-going pregnancies.
Contraceptive use and incidence of unplanned
pregnancy
Figure 2c compares incidence of unplanned pregnancy
according to baseline unmet need for contraception. These curves
illustrate that women with a baseline unmet need for reliable
contraception had a higher incidence of unplanned pregnancy
during study follow-up as compared to women who reported use
of a reliable contraceptive (log-rank p,0.01). When considering
time-varying contraceptive use and incidence of unplanned
pregnancy (Figure 2d), women reporting condom use alone to
prevent pregnancy had similar cumulative incidence rates of
unplanned pregnancies to women reporting no reliable method
use; women on HC had significantly lower incidence rates.
Nine of 105 unplanned pregnancies (8.6%) were hormonal
contraceptive failures. All contraceptive failures were confirmed
through review of family planning records. One COC failure
appears to have been due to poor compliance and is excluded
from the subsequent calculations. The incidence rate of unplanned
pregnancy on HCs was 4.4/100 PY [2.2–8.9], including one
failure not related to compliance on a COC (5.8/100 PY [1.4–
23.0]) and seven injectable failures (2 DMPA, 5 NET-EN) (4.2
[1.9–9.4]). Five of the seven injectable failures were estimated to
have occurred during the final two weeks of the injection cycle.
Regarding the ART regimens of women experiencing HC failures,
seven women were on nevirapine-based ART and one failure was
on an efavirenz-based regimen. At baseline 94% of women were
on first-line ART including nevirapine (52%) or efavirenz (42%).
Prevalence of contraceptive use and predictors of unmet
need for contraception
Prevalence of baseline HC use in the cohort was 28.6% (243/
850). Progestin-only injectables were the most commonly reported
method (n=192), followed by COCs (n=46), implants (n=4) and
IUD (n=1).
Amongst women sexually active in the past three months and
not trying to conceive, 54% of women reported consistent condom
use and 33% were using HC, including 15% dual method users.
Twenty-eight percent of sexually active women had an unmet
need for reliable contraception at baseline. In the multivariate
analysis (Table 3), women initiating ART in the past year had a
50% higher prevalence of unmet need for contraception as
compared to women on ART for greater than one year (aPR 1.5
[95% CI 1.1–2.0], p=0.01). Having a CD4 cell count #200 was
significantly associated with an unmet need for reliable contra-
ception in comparison to other CD4 categories.
Figure 2. Kaplan-Meier plots of time-to-first pregnancy amongst women on antiretroviral therapy (ART), South Africa. Time-to-first
pregnancy is depicted by: (A) total years-on-ART; (B) time-varying fertility intentions; (C) baseline need for contraception; and (D) time-varying
contraceptive use during study follow-up. HC=hormonal contraception.
doi:10.1371/journal.pone.0036039.g002
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Fewer than half (48%) of women reported that an HIV provider
had discussed hormonal contraception with them. Of the 243
women using HC, 82 (34%) reported experiencing problems with
their method. Over three-quarters of all problems (79%) were
related to menstrual bleeding, including amenorrhea (n=31),
heavy bleeding (n=14) or other irregular bleeding (n=20). The
majority (61%) of women experiencing problems with their HC
method had not discussed these with any provider. Furthermore,
in this setting, women see different providers for their HIV
treatment and contraceptive care and over half of women (55%)
had not informed their contraceptive care providers of their HIV-
status.
Amongst those not currently trying to conceive and not using
HC, the most commonly reported reasons for not using HC were:
already using condoms (n=184, 36%), irregular bleeding (n=61,
12%), and general side effects (n=53, 10%).
Discussion
We have documented high rates of unplanned pregnancies after
ART initiation in South Africa; these high rates are at least
partially driven by a high unmet need for contraception during the
first year of ART. These findings underscore the need to counsel
women about pregnancy risk at time-of-ART initiation and
consistently thereafter. Moreover, these results provide prelimi-
nary data on the magnitude of health risks that could in part be
averted through the integration of contraception services into
ART treatment services. Preventing unwanted pregnancies can
reduce maternal morbidity risks related to unsafe abortion and
minimize any negative impacts of pregnancy on health, especially
Table 3. Predictors of unmet need for contraception amongst sexually active women not trying to conceive (n=675).
Univariate PR
a p-value Multivariate aPR
b p-value
[95% CI] [95% CI]
Age (per 5 years) 0.78 [0.67–0.90] 0.001 0.90 [0.77–1.05] 0.169
Employed
No REF
Yes 0.91 [0.71–1.17] 0.477
Education Completed
None - grade 10 REF
Grade 11–12 0.89 [0.68–1.17] 0.415
Post grad degree/certificate 0.91 [0.60–1.39] 0.660
Income Category, (USD/mo)
$0–200 REF REF
$201–400 0.81 [0.60–1.08] 0.151 0.85 [0.64–1.13] 0.262
.$400 0.69 [0.50–0.94] 0.019 0.74 [0.55–1.01] 0.058
Married/Cohabitating
No REF
Yes 0.82 [0.64–1.05] 0.108
Number of living children
None REF REF
One 0.82 [0.61–1.10] 0.190 0.91 [0.68–1.21] 0.497
Two or more 0.57 [0.41–0.79] 0.001 0.72 [0.51–1.01] 0.057
Baseline CD4 category at enrollment, cells/ml
#200 REF REF
201–350 0.48 [0.35–0.68] ,0.001 0.57 [0.41–0.80] 0.001
351–500 0.52 [0.37–0.72] ,0.001 0.67 [0.47–0.95] 0.026
.500 0.51 [0.36–0.72] ,0.001 0.74 [0.49–1.11] 0.147
Time since ART initiation
.1 yr (ART experienced) REF REF
#1 yr (recent initiator) 1.88 [1.47–2.42] ,0.001 1.47 [1.08–1.99] 0.013
Prior exposure to intimate partner violence
No REF REF
Yes 1.37 [0.98–1.92] 0.069 1.35 [0.98–1.88] 0.069
Concurrent partners
No REF REF
Yes 1.54 [1.14–2.07] 0.004 1.41 [1.06–1.87] 0.017
a,bPrevalence Ratios (PRs) and adjusted Prevalence Ratios (aPRs) estimated using robust Poisson regression.
doi:10.1371/journal.pone.0036039.t003
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unintended pregnancies is also critical to reduce MTCT risks,
particularly in the period soon after ART initiation before HIV
viral suppression has been achieved.
The incidence rate of 21.6 pregnancies/100 PY is twice as high
as that recently reported amongst HIV uninfected women in a
multi-site HIV Prevention Trials Network study (HPTN 035),
however HC use was also two times higher in HPTN 035 [19].
When comparing our study’s pregnancy incidence rates to those of
other studies amongst HIV infected women, the overall incidence
is similar to a recent report from Uganda, but higher than several
other studies [11,12,20,21]. As many studies rely on less frequent
pregnancy testing and/or self-report, it is not surprising that the
pregnancy rates reported in this study are higher. In this setting
105/170 (62%) pregnancies were unplanned and of these, 57
(54%) were not carried to term; had we relied on self-report and
not tested regularly for pregnancy, many of these pregnancies
would likely have remained undetected. The high burden of
termination of pregnancy, 26% of all pregnancies and 38% of
unplanned pregnancies, further highlights the consequences of
unmet need for contraception in this population.
We might have expected women recently initiating ART to
have had lower rates of pregnancy during this period of
immunological reconstitution. Pregnancy incidence rates, howev-
er, were highest during the first year after ART initiation and
statistically comparable to those of more ART-experienced
women. Unmet contraceptive need was also greatest in the year
following ART initiation. It is particularly concerning that by two
years on ART, 25% of women had at least one unplanned
pregnancy and this number increased to 35% by three years on
ART.
While family planning is not a routine concern of HIV staff
during ART initiation, these results suggest that it should be an
immediate priority for providers and discussed regardless of CD4
cell count or perceived risk of pregnancy. Sexual activity is likely to
increase after ART initiation as health improves, and in the
absence of counselling and family planning, high rates of
unplanned pregnancies will occur even amongst women with
low CD4 cell counts. Counselling should emphasize that
pregnancy risk is similar in women on ART as compared to
HIV-uninfected women, and that women may be at risk for
pregnancy while amenorrheic [22]. Side effects, including
menstrual irregularities, may be a cause for greater concern
amongst HIV-infected women and should be addressed in
counselling. Down-referral ART sites offer HC onsite, though in
separate rooms by separate providers. We did not see a difference
in unplanned pregnancies between sites however it is likely that
rates at primary health care down-referral sites would be even
higher if contraception were unavailable on-site. Further integra-
tion of HC services into ART care may improve method uptake,
streamline counselling messages and decrease clinic visit times.
At baseline only one-third of sexually active women not
intending to conceive were using HC. Our findings reinforce
results from other studies, however, that condom use alone does
not substantially decrease pregnancy risk and is generally not a
reliable method of contraception for women on ART [11,23].
Limited uptake of HC may be in part due to poor patient-provider
communication. HIV providers may be wary of promoting HC
based on suspicions of condom migration, mixed evidence around
the impact of HC on women’s health, due to concerns over
potential drug interactions resulting in reduced HC efficacy, or
due to inadequate training in HC service provision [24–27].
Recent findings that HCs may increase HIV transmission from
women not using ART to uninfected male partners are cause for
further concern and will need to be considered alongside maternal
and infant risks associated with unintended pregnancies [28].
We reported eight conceptions in women using HC that were
not failures attributed to compliance. Seven of the failures were in
women on NVP-based regimens. Further attention to this issue is
warranted as the observed failure rate of 4.2/100 PY on injectable
methods is much higher than 0.3/100 PY, the estimated failure
rate for perfect use in non-ART populations [29]. As five out of
the seven injectable failures occurred towards the end of the
injection cycle, providers may need to consider reducing the time
between injections for women on ART. IUDs have been shown to
be safe for HIV-positive women and could be promoted as an
alternative to avoid possible drug interactions [24].
This study has some limitations. Hormonal contraception was
self-reported and while condom use was recorded throughout the
study, consistency of condom use and frequency of sex were only
assessed at baseline and during the final interview. Nevertheless,
the incidence analysis using baseline unmet need provides similar
inferences to the analysis using longitudinal contraception use.
Other variables including changes in partnership status and last
menstrual period were not collected at each visit, but would have
been informative as they may reflect changes in pregnancy risk.
Exit interviews indicated that 91% of women were in relationships
at end of follow-up as compared to 93% at baseline. Although
some women did experience changes in relationships, partnership
gap times cannot be determined in our data. Another concern may
be that there was a selection bias into the study such that women
more likely to conceive were more likely to participate. We
intentionally limited the study population to sexually active women
aged 18–35, as these are the women most at-risk for pregnancy
and the population to which these findings should be targeted in a
clinical setting. While it is possible that women desiring more
children were more likely to participate, study recruitment
messages expressed a general interest in women and reproductive
health. Furthermore, the high rate of pregnancy termination
observed suggests that the unplanned pregnancies genuinely were
unwanted.
As all women in our population are on ART, we cannot
attribute the high rates of unplanned pregnancy to ART initiation.
The findings from this study do suggest however, that reproductive
health-related risks are neglected around the time-of-ART
initiation and pregnancy risk is high in the year following ART
initiation. In order to decrease unintended pregnancies and
associated health risks in ART populations, HIV providers should
be trained in HC provision. ART providers have experience in
counselling patients related to adherence and side effects, and are
a point of care women routinely access. While more research is
necessary around contraceptive failures on ART, the risk of
pregnancy on HC remains significantly lower than in women
using condoms alone. Contraception, including HC and IUDs
alongside condoms, should be routinely offered to women on
ART. Information regarding benefits and side effects of different
methods should be provided in order to ensure informed choices
are supported and unnecessary method discontinuation avoided.
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